Evidence map›Paper›PMID 41311396›Full record

ArticleActa pharmaceutica Sinica. B2025

Erratum: Author correction to "Structurally defined tandem-responsive nanoassemblies composed of dipeptide-based photosensitive derivatives and hypoxia-activated camptothecin prodrugs against primary and metastatic breast tumors" [Acta Pharm Sin B 12 (2022) 952-966].

Mengchi Sun, Hailun Jiang, Tian Liu, Xiao Tan, Qikun Jiang, Bingjun Sun, Yulong Zheng, Gang Wang, Yang Wang, Maosheng Cheng and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Mengchi SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Hailun JiangKey Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, Shenyang 110016, China.
Tian LiuWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Xiao TanWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Qikun JiangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Bingjun SunKey Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, Shenyang 110016, China.
Yulong ZhengSchool of Materials Science and Engineering, Ocean University of China, Qingdao 266100, China.
Gang WangCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Yang WangCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Maosheng ChengKey Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, Shenyang 110016, China.
Zhonggui HeWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jin SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.apsb.2021.08.008.].

Identifiers

PMID41311396
PMCPMC12647991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.